CV (CapsoVision) YoY EBITDA Growth: -53.61% (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CV CapsoVision Inc CV
10 GF Score
Price $6.42
! 1 Warning Sign
View Full Analysis

What is CapsoVision YoY EBITDA Growth?

CapsoVision CV -4.86% 10 YoY EBITDA Growth is -53.61% as of Jun. 2026. GuruFocus rates CV with a GF Score™ of 10/100. The stock has 1 warning sign investors should review.

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. CapsoVision's YoY EBITDA Growth for the quarter that ended in Jun. 2026 was -53.61%.

CapsoVision's EBITDA per Share for the three months ended in Jun. 2026 was $-0.15.

CapsoVision YoY EBITDA Growth Historical Data

* Premium members only.

The historical data trend for CapsoVision's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CapsoVision YoY EBITDA Growth Chart

CapsoVision Annual Data
Trend Dec23 Dec24 Dec25
YoY EBITDA Growth
0.00 -47.54 -26.97

CapsoVision Quarterly Data
Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
YoY EBITDA Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 23.02 -22.30 -60.82 -29.20 -53.61
CV
10GF Score
CapsoVision Inc CV
YoY EBITDA Growth is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

CapsoVision YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

CapsoVision's YoY EBITDA Growth for the fiscal year that ended in Dec. 2025 is calculated as:

YoY EBITDA Growth (A: Dec. 2025 )
=(EBITDA per Share (A: Dec. 2025 )-EBITDA per Share (A: Dec. 2024 ))/ | EBITDA per Share (A: Dec. 2024 ) |
=(-0.532--0.419)/ | -0.419 |
=-26.97 %

CapsoVision's YoY EBITDA Growth for the quarter that ended in Jun. 2026 is calculated as:

YoY EBITDA Growth (Q: Jun. 2026 )
=(EBITDA per Share (Q: Jun. 2026 )-EBITDA per Share (Q: Jun. 2025 )) / | EBITDA per Share (Q: Jun. 2025 )) |
=(-0.149--0.097)/ | -0.097 |
=-53.61 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about YoY EBITDA Growth →
What does a YoY EBITDA Growth of -53.61% mean?
CapsoVision (CV) has a YoY EBITDA Growth of -53.61% as of Jun. 2026. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for CapsoVision and its competitors.
Is CapsoVision's YoY EBITDA Growth too high?
CapsoVision's current YoY EBITDA Growth is -53.61%. Overall, CapsoVision has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does CapsoVision's YoY EBITDA Growth compare to LAB and ELMD?
CapsoVision's YoY EBITDA Growth of -53.61% can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good YoY EBITDA Growth for a Medical Devices & Instruments company?
A good YoY EBITDA Growth depends on the Medical Devices & Instruments industry context. However, YoY EBITDA Growth should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high YoY EBITDA Growth mean?
A high YoY EBITDA Growth can signal that a stock is expensive relative to its fundamentals. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for CapsoVision and its competitors. CapsoVision's current YoY EBITDA Growth is -53.61%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CapsoVision stock overvalued right now?
CapsoVision (CV) has a current YoY EBITDA Growth of -53.61%. The current YoY EBITDA Growth is -53.61%. CapsoVision's overall GF Score™ is 10/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is YoY EBITDA Growth calculated?
YoY EBITDA Growth is calculated from a company's financial statements. For CapsoVision (CV), the current YoY EBITDA Growth is -53.61% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

CapsoVision Business Description

Other Exchanges H6U:Germany
Address 18805 Cox Avenue, Suite 250, Saratoga, CA, USA, 95070
CapsoVision Inc is a commercial-stage medical technology enterprise that innovates, manufactures, and markets endoscopic video imaging devices focused on internal imaging of the gastrointestinal (GI) system. The company's core technology platform is an orally ingestible capsule including multiple cameras facilitating 360-degree imaging, light-emitting diodes for measurement, onboard memory storage, and battery life permitting recording and onboard storage of video images. CapsoVision's products consist of the on-market CapsoCam Plus, directed at the small intestines, and the in-development CapsoColon 3D, directed at the large intestines. Geographically, the company generates the majority of its revenue from the United States.
10GF Score

Get the complete analysis for CV

YoY EBITDA Growth is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$6.42
Price